Detalhe da pesquisa
1.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
J Allergy Clin Immunol
; 151(1): 172-181, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195170
2.
Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis.
Br J Clin Pharmacol
; 89(10): 3139-3151, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232215
3.
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
J Allergy Clin Immunol
; 149(3): 977-987.e14, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34403658
4.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 397(10290): 2169-2181, 2021 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023009
5.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Lancet
; 397(10290): 2151-2168, 2021 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023008
6.
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
Lancet
; 394(10214): 2108-2117, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732180
7.
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Blood
; 131(17): 1910-1919, 2018 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29437592
8.
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Br J Haematol
; 182(4): 504-512, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29873072
9.
Tetramers reveal IL-17-secreting CD4+ T cells that are specific for U1-70 in lupus and mixed connective tissue disease.
Proc Natl Acad Sci U S A
; 112(10): 3044-9, 2015 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25713364
10.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
N Engl J Med
; 371(3): 213-23, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881631
11.
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Lancet Oncol
; 17(10): 1409-1418, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27637985
12.
A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.
JAAD Int
; 6: 27-36, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34988493
13.
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
Arthritis Rheumatol
; 74(1): 70-80, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196498
14.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
JAMA Dermatol
; 158(4): 404-413, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262646
15.
IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice.
J Clin Invest
; 118(4): 1417-26, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18340381
16.
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
JAMA Dermatol
; 157(9): 1047-1055, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34347860
17.
Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States.
J Clin Rheumatol
; 15(5): 226-9, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19590444
18.
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
JAMA Oncol
; 4(5): 712-716, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29470582
19.
Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1.
Arthritis Rheumatol
; 68(5): 1233-44, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26636548
20.
Measuring outcomes in systemic lupus erythematosus clinical trials.
Expert Rev Pharmacoecon Outcomes Res
; 11(4): 455-68, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21831027